A Cork biopharma company has secured European funding of €5.66 million for research into the treatment of premature newborns suffering from hypotension. BrePco Biopharma is working with Cork University Hospital and a number of university research centres in Ireland, Europe and Canada to address the condition, a common problem among the most premature infants which can lead to brain injury and death.

BrePco’s Paul Breen said the investment was “a significant milestone for our company, as well as for the researchers in Cork University Maternity Hospital with whom we have been working for the last two years”. Four of the eight clinical trial sites for the project are in Ireland.